New hope for tough breast cancer: targeted drug HLX43 enters phase 2 trial
NCT ID NCT07459738
First seen Apr 18, 2026 · Last updated May 23, 2026 · Updated 4 times
Summary
This phase 2 trial tests a new drug called HLX43 in 60 people with a specific type of advanced breast cancer (HR+, HER2-) that has worsened despite standard hormone therapy. The drug is an antibody-drug conjugate that targets PD-L1, a protein on cancer cells, to deliver a toxic payload directly. The goal is to see if it can shrink tumors or slow cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.